07:37 AM EST, 11/03/2025 (MT Newswires) -- Axsome Therapeutics ( AXSM ) reported a Q3 net loss Monday of $0.94 per diluted share, narrowing from a loss of $1.34 a year earlier. Analysts surveyed by FactSet expected a loss of $0.82. Total revenue for the quarter ended Sept. 30 was $171 million, compared with $104.8 million a year earlier. Analysts...

Overview * L.B. Foster Q3 sales up 0.6%, driven by Infrastructure growth, Rail sales down 2.2% * Adjusted EBITDA for Q3 down 7.9%, reflecting lower profitability * Net income for Q3 fell 87.9% due to prior year's tax adjustment Outlook * L.B. Foster revises 2025 guidance, expecting 22% increase in Adjusted EBITDA on 2% sales growth * Company expects Q4...

LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...

07:38 AM EST, 11/03/2025 (MT Newswires) -- ECARX ( ECX ) reported Monday a breakeven in Q3, swinging from a loss of $0.14 per share a year earlier. A single analyst polled by FactSet expected a loss of $0.03. Revenue for the quarter ended Sept. 30 was $219.9 million, up from $198.2 million a year earlier. A single analyst surveyed...